Standard Dosing Schedules for Nivolumab
Nivolumab (Opdivo), a PD-1 inhibitor used in cancers like melanoma, lung cancer, and renal cell carcinoma, has FDA-approved dosing that varies by indication, line of therapy, and combination status. The most common monotherapy schedules are every 2 weeks (Q2W) or every 4 weeks (Q4W) at 240 mg or 480 mg intravenously.[1]
- Monotherapy (flat dose): 240 mg every 2 weeks or 480 mg every 4 weeks.[1]
- Weight-based dosing (older standard): 3 mg/kg every 2 weeks, still listed for some indications.[1]
Doses are infused over 30 minutes, with adjustments for toxicity or body weight in specific cases.
How Dosing Differs by Cancer Type
Schedules align with tumor-specific approvals:
- Melanoma (unresectable/metastatic): 240 mg Q2W or 480 mg Q4W monotherapy; or 1 mg/kg nivolumab + 3 mg/kg ipilimumab Q3W for 4 doses, then 240 mg Q2W.[1]
- Non-small cell lung cancer (NSCLC): 240 mg Q2W or 480 mg Q4W post-platinum chemo; combinations like 360 mg Q3W with ipilimumab adjust frequency.[1]
- Renal cell carcinoma: 240 mg Q2W or 480 mg Q4W with ipilimumab initially, then maintenance.[1]
- Hodgkin lymphoma: 240 mg Q2W.[1]
Always check the label for the exact indication, as off-label use follows similar patterns.
Why Multiple Frequencies Exist
The Q2W and Q4W options stem from pharmacokinetic data showing sustained PD-1 exposure. Phase 3 trials like CheckMate 067 (melanoma) and 017/057 (NSCLC) supported both, with Q4W reducing infusion burden—real-world use has shifted toward it for convenience.[2][1] No head-to-head superiority exists; choice depends on patient factors like travel or venous access.
What Happens with Dose Delays or Adjustments
Hold nivolumab for grade 2 immune-related adverse events (irAEs); resume at same dose upon resolution. Permanently discontinue for grade 4 toxicity or recurrent grade 3. No routine dose capping by weight in flat-dose regimens.[1]
Common Patient Questions on Scheduling
Patients often ask about home administration (not standard; outpatient infusions typical) or switching frequencies—physicians can per label without retitration.[3] Pregnancy category D; avoid in active autoimmune disease unless benefits outweigh risks.
[1]: [FDA Opdivo Label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s ws.html)
[2]: CheckMate Trial Data via NCCN Guidelines
[3]: ASCO Immunotherapy Guidelines